Literature DB >> 33617204

Daratumumab for Antibody-mediated Rejection in Heart Transplant-A Novel Therapy: Successful Treatment of Antibody-mediated Rejection.

Cristina Aguilera Agudo1, Manuel Gómez Bueno1, Isabel Krsnik Castello2.   

Abstract

Entities:  

Year:  2021        PMID： 33617204     DOI： 10.1097/TP.0000000000003505

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  3 in total

1.  Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.

Authors:  Katharina A Mayer; Klemens Budde; Philip F Halloran; Konstantin Doberer; Lionel Rostaing; Farsad Eskandary; Anna Christamentl; Markus Wahrmann; Heinz Regele; Sabine Schranz; Sarah Ely; Christa Firbas; Christian Schörgenhofer; Alexander Kainz; Alexandre Loupy; Stefan Härtle; Rainer Boxhammer; Bernd Jilma; Georg A Böhmig
Journal:  Trials       Date:  2022-04-08       Impact factor: 2.279

Review 2.  Targeting CD38 in Neoplasms and Non-Cancer Diseases.

Authors:  Wojciech Szlasa; Jakub Czarny; Natalia Sauer; Katarzyna Rakoczy; Natalia Szymańska; Jakub Stecko; Maksymilian Kołodziej; Maciej Kaźmierczak; Ewa Barg
Journal:  Cancers (Basel)       Date:  2022-08-28       Impact factor: 6.575

Review 3.  HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers.

Authors:  Nizar Joher; Marie Matignon; Philippe Grimbert
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.